Philip Bejon/Vaccine

Dynamics and role of antibodies to Plasmodium falciparum merozoite antigens in children living in two settings with differing malaria transmission intensity.Kangoye DT, Mensah VA, Murungi LM, Nkumama I, Nebie I, Marsh K, Cisse B, Bejon P, Osier FH, Sirima SB, MVVC Infant Immunology Study Group
Vaccine, (2016). 34:160-6

A threshold concentration of anti-merozoite antibodies is required for protection from clinical episodes of malaria.Murungi LM, Kamuyu G, Lowe B, Bejon P, Theisen M, Kinyanjui SM, Marsh K, Osier FH
Vaccine, (2013). 31:3936-42

Response to "Poor control vaccines in two randomised trials of malaria vaccine?".Bejon P, Abdulla S, Lusingu J, Olotu A, Leach A, Lievens M, Tanner M, von Seidlein L
Vaccine, (2009). 27:4745-6

Prevalence of serum neutralizing antibodies against chimpanzee adenovirus 63 and human adenovirus 5 in Kenyan children, in the context of vaccine vector efficacy.Dudareva M, Andrews L, Gilbert SC, Bejon P, Marsh K, Mwacharo J, Kai O, Nicosia A, Hill AV
Vaccine, (2009). 27:3501-4

Longitudinal analyses of immune responses to Plasmodium falciparum derived peptides corresponding to novel blood stage antigens in coastal Kenya.Agak GW, Bejon P, Fegan G, Gicheru N, Villard V, Kajava AV, Marsh K, Corradin G
Vaccine, (2008). 26:1963-71

Clearing asymptomatic parasitaemia increases the specificity of the definition of mild febrile malaria.Bejon P, Mwangi T, Lowe B, Peshu N, Hill AV, Marsh K
Vaccine, (2007). 25:8198-202

Immunogenicity of the candidate malaria vaccines FP9 and modified vaccinia virus Ankara encoding the pre-erythrocytic antigen ME-TRAP in 1-6 year old children in a malaria endemic area.Bejon P, Mwacharo J, Kai OK, Todryk S, Keating S, Lang T, Gilbert SC, Peshu N, Marsh K, Hill AV
Vaccine, (2006). 24:4709-15